Shanghai Changzheng Hospital
Shanghai Changzheng Hospital
Shanghai, China8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases | autoimmune disease, immune system disorder | Recruiting | Early phase 1 | 2026-09-18 | NCT07122076 | |
| CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer | Locally Advanced Rectal Cancer | Active, not recruiting | Phase 2 | 2026-09-02 | NCT05585814 | |
| KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome | Abnormalities, Multiple, Blood Protein Disorders, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, POEMS syndrome, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Recruiting | Phase 2 | 2026-06-17 | NCT07652879 | |
| Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, Osteoporotic Fractures, bone disorder, bone fracture, injury, metabolic disease, musculoskeletal system disorder, osteoporosis | Recruiting | Not applicable | 2026-01-12 | NCT05866029 | |
| Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes | Insulin Resistance, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Not stated | 2025-09-30 | NCT07198932 | |
| A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography | cardiovascular disorder | Recruiting | Not stated | 2025-08-21 | NCT07133516 | |
| CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer | Locally Recurrent Colorectal Cancer | Recruiting | Phase 2 | 2025-03-18 | NCT06881537 | |
| Study of CT071 Injection in RRMM or PPCL | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Early phase 1 | 2025-01-07 | NCT05838131 |